• Associations of interferon level and clinical signs of various types of human papillomavirus

Associations of interferon level and clinical signs of various types of human papillomavirus

PERINATOLOGY AND PEDIATRIC. UKRAINE. 2018.3(75):56-60; doi 10.15574/PP.2018.75.56

Grishchenko O. V., Bobritskaya V. V.
Kharkiv Medical Academy of Postgraduate Education, Ukraine

Objective: to determine the compliance of the serum interferon level (IFN) with the clinical signs of the female reproductive system diseases in the presence of various types of human papillomavirus (HPV).

Materials and methods. In total 250 women aged 23–37 years were divided into two groups. The main group I comprised patients with clinical manifestations of human papillomavirus infection (PVI). The control group was divided into two subgroups: group IIA included women who had HPV-positive PCR without clinical signs of PVI, in group IIB were enrolled clinically healthy women with HPV-negative PCR results. Digene HPV 6,11,16,18,26,31,33,35,39,44,45,51,52,53,56,58,59,68,69,73,82 test with viral load was performed; as well as examination for bacteria, chlamydia, myco- and ureaplasma. The IFN level in blood serum was detected in all patients.

Results. In group I, the identified HPV types were responsible for the dysplastic processes of the genital organs. Viral load less than 3 Lg was observed in 28 (56.0%) patients of group I and 18 (36.0%) of group IIA, from 3 Lg to 5 Lg – in 67 (44.6%) patients of group I and 4 (8.0%) of group IIA. In group I, the level of 2–4 Lg was associated with high-grade dysplastic changes in the genital organs and skin of the perineal area, which require electrosurgical treatment. In the control subgroup with a higher level of serum interferon, clinical manifestations of PVI were not diagnosed.

Conclusions. The HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51, 52, 53, 56, 58, 59, 68, 69, 73, 82 are associated with dysplastic diseases of the cervix, vagina, external genitalia; the prognosis of the disease and severity of dysplastic processes is connected with the viral load of 3 Lg to 5 Lg, as well as the IFN serum level. These tests may be recommended to predict the disease development and use in the comprehensive pregravid preparation.

Key words: human papillomavirus, viral load, serum interferon, dysplasia.

References

1. Galitskaya MG, Ivardava MI. (2009) Papillomavirus infection in boys and young men. The possibilities of its primary prevention. Pediatric Pharmacology. 6(2): 12-14.

2. Golovina DA, Trofimova OB, Ermilova VD et al. Complex of molecular genetic and immunohistochemical methods for detection of human papillomavirus in the bladder cancer epithelium. Bull Exp Biol Med. 2014; 157(1): 70-73. doi 10.1007/s10517-0142494-0.

3. Eremin VF, Vergeichik GI, Stribuk JA. (2010) Human Papillomaviruses: Some Aspects of Pathogenesis and Modern Classification. Health and environment problems. 3(24): 22-24.

4. Kachalina TS, Kachalina OV, Vakhabova GA, Zinovyeva MS (2017) Analysis of the course of pregnancy and labor after the treatment of various forms of HPV-associated cervical disease. Medical Almanac. 6(51): 36-39.

5. Kachalina TS, Kachalina OV, Vakhabova GA. (2018). The course of pregnancy and childbirth in patients who had previously undergone the pathology associated with the human papilloma virus. Obstetrics and gynecology. 7: 62-66.

6. Klinyshkova TV, Buyan MS. (2018). For cervical precancer in conditions of persistent human papillomavirus infection. Mother and child in Kuzbass. 1(72): 77-80.

7. Babasha S, Soliemani M. (2011). The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 47(8): 1127—37. https://doi.org/10.1016/j.ejca.2011.02.008; PMid:21402473

8. Bodily J, Laimins LA. (2011). Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 9(1): 33—39. https://doi.org/10.1016/j.tim.2010.10.002.

9. Gorbunova OV, Zarichanska HV. (2018). Efficiency of using antifungal drugs in women with vaginal candidiasis on the background of papillomavirus infection. Perinatologiya i pediatriya. 2(74): 31—34. doi 10.15574/PP.2018.74.31

10. Munoz N at al. (2010). Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer. 102(5):325—39. https://doi.org/10.1093/jnci/djp534; PMid:20139221

Article received: Jun 23, 2018. Accepted for publication: Sep 02, 2018.